EGFR-directed treatments in SCCHN

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 672-673

  Vokes, Everett E ^a   Seiwert, Tanguy Y ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CETUXIMAB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN P16; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG RECEPTOR BINDING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LETTER; LUNG ADENOCARCINOMA; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; OROPHARYNX CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WART VIRUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 84879783298     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70215-8     Document Type: Letter

References (11)

1. Grandis JR, Tweardy DJ Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993, 53:3579-3584.
2. Seiwert TY, Fayette J, Cupissol D, et al. A randomized, open-label, phase ii study of afatinib (bibw 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck- final data. Multidisciplinary Head and Neck Cancer Symposium; Phoenix, AZ, USA; Jan 26-28, 2012. LBPV10.
3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
4. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Proc Am Soc Clin Oncol 2011, 29:550. (abstr).
5. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
6. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013, published online June 6. http://dx.doi.org/10.1016/S1470-2045(13)70181-5.
7. Mendez E Biomarkers of HPV infection in oropharyngeal carcinomas: can we find simplicity in the puzzle of complexity?. Cancer Res 2012, 72:4896-4898.
8. Lingen MW, Xiao W, Schmidt A, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncology 2012, 49:1-8.
9. Hayes DN, Grandis JR, El-Naggar AK. Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 6-10, 2013. 1117.
10. Young RJ, Rischin D, Fisher R, et al. Relationship between epidermal growth factor receptor status, p16INK4A, and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2011, 20:1230-1237.
11. Lui WYV, Van Allen E, Li H, et al. Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. American Association for Cancer Research Annual Meeting; Washington, DC, USA; April 6-10, 2013. 4565.